Adverse Effects of Intravenous Immunoglobulin

Drug Safety

Volumn 9, Issue 4, 1993, Pages 254-262

  Misbah, Siraj A ^a   Chapel, Helen M ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD GROUP A ANTIBODY; BLOOD GROUP ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ALOPECIA; ANAPHYLAXIS; ASEPTIC MENINGITIS; COOMBS TEST; DRUG INFUSION; DRUG SAFETY; ECZEMA; ERYTHEMA MULTIFORME; ERYTHROCYTE; FLUSHING; HEADACHE; HEMOLYSIS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; LOW BACK PAIN; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MYCOSIS; NAUSEA; REVIEW; SKIN DISEASE; UVEITIS; VASCULITIS; VIRUS INACTIVATION; VIRUS TRANSMISSION; WHEEZING;

HUMAN; IMMUNOGLOBULINS, INTRAVENOUS;

EID: 0027522107     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-199309040-00003     Document Type: Review

References (64)

1. Use of intravenous gammaglobulin in antibody immunodeficiency: results of a multicenter controlled trial
2. Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy. Correspondence
3. Intravenous administration of human gammaglobulin
4. Acute cryoglobulinemic renal failure after intravenous infusion of gammaglobulin
5. Eczema after intravenous infusion of immunoglobulin
6. Mechanism of therapeutic effect of high dose intravenous immunoglobulin: attenuation of acute complement dependent immune damage in a guinea pig model
7. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency
8. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies
9. Hemolytic anaemia following intravenous gammaglobulin administration
10. Anaphylactic reactions after gammaglobulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA
11. Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenia purpura
12. Intravenous immune globulin and acute aseptic meningitis. Correspondence
13. Alopecia after immunoglobulin infusion. Correspondence
14. Safety of immunoglobulin therapy in patients with multiple myeloma
15. Transient neutropenia induced by intravenous immune globulin. Correspondence
16. Chemical, clinical and immunological studies of the products of human plasma fractionation
17. Immune haemolysis, disseminated intravascular coagulation and serum sickness after large doses of immunoglobulin given intravenously for Kawasaki’ s disease
18. IVIG for the prevention of infection in chronic lymphocytic leukemia
19. Use of high dose intravenous immunoglobulin in systemic lupus erythematosus: report of three cases
20. Intravenous immune globulin: a cautionary tale. Correspondence
21. Uveitis and antineutrophil cytoplasmic antibody in immunoglobulin batches. Correspondence
22. High dose intravenous immune globulin and acute renal failure. Correspondence
23. Anti-HCV screening and plasma fractionation: the case against. Correspondence
24. Transient neutropenia induced by intravenous immune globulin. Correspondence
25. Crossover study of immunoglobulin replacement therapy in patients with low grade B cell tumours
26. Predictors of infection in chronic lymphocytic leukaemia (CLL)
27. Screening for hepatitis C virus antibody in plasma for fractionation. Correspondence
28. Hyperviscosity in HIV infected children — a potential hazard during intravenous immunoglobulin therapy
29. Anaphylaxis after administration of gamma globulin for hypogammaglobulinemia. Correspondence
30. Update on IgA and IgG subclass deficiency
31. Seroconversion for Hepatitis C virus antibody in bone marrow recipients treated with immune globulin. Correspondence
32. Treatment of systemic vasculitis with pooled intravenous immunoglobulin
33. Administration of immune globulin associated with aseptic meningitis. Correspondence
34. Renal toxicity of intravenous immunoglobulin
35. Non-A non-B hepatitis occuring in agammaglobulinaemic patients after intravenous immunoglobulin
36. Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin
37. Improvement of histological and immunological change in steroid and immunosuppressive drug resistant lupus nephritis by high dose intravenous gamma globulin
38. Hypogammaglobulinaemia in the United Kingdom
39. Elimination of infectious retroviruses during preparation of immunoglobulins
40. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection
41. A single intravenous infusion of gammaglobulin as compared with four infusions in the treatment of acute Kawasaki syndrome
42. The treatment of Kawasaki syndrome with intravenous gamma globulin
43. Haemolysis induced by intravenously administered immunoglobulin
44. Non-A non-B hepatitis and intravenous immunoglobulin. Correspondence
45. Alteration in circulating neutrophil CR3 density associated with immunoglobulin infusion
46. Renal failure and intravenous immunoglobulin
47. Recurrent aseptic meningitis complicating intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy
48. Intravenous immune globulin and aseptic meningitis
49. Pulmonary and renal toxicity of intravenous immunoglobulin
50. Effect of high dose intravenous immunoglobulin therapy on blood rheology
51. Erythema multiforme after intravenous immunoglobulin
52. Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease
53. Antiidiotypes against antineutrophil cytoplasmic antigen autoantibodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis
54. Intravenous IgG for glomerulonephritis and renal function
55. High dose intravenous IgG treatment and renal function
56. Adverse effects of intravenous immunoglobulins
57. High dose intravenous immune globulin may impair host defences
58. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis
59. Antiidiotypic suppression of autoantibodies to factor VIII (anti-haemophilic factor) by high dose intravenous gamma globulin
60. Acute renal failure resulting from intravenous immunoglobulin therapy
61. A randomised trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome
62. Transmission of non-A non-B hepatitis by pH4 treated intravenous immunoglobulin
63. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Correspondence
64. Appropriate uses of human immunoglobulin in clinical practice: memorandum from an IUIS/WHO meeting